14
views
0
recommends
+1 Recommend
1 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterization of patients with adrenal insufficiency and frequent adrenal crises

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          This study aimed to characterize the clinical and biochemical features of patients with primary (PAI) and secondary (SAI) adrenal insufficiency who developed adrenal crises (ACs) and estimate the incidence of ACs in these patients.

          Design

          Retrospective case-control analysis of the European Adrenal Insufficiency Registry (EU-AIR; NCT01661387).

          Methods

          Two thousand six hundred and ninety-four patients with AI (1054 PAI; 1640 SAI) enrolled in EU-AIR. Patients who developed ≥ 1 AC were matchd 1:3 with patients without ACs for age, sex and AI type. Data were collected at baseline and follow-up (mean ± s.d.: PAI 3.2 ± 1.7 years; SAI 2.9 ± 1.7 years).

          Results

          One hundred and forty-eight out of 2694 patients (5.5%; n  = 84 PAI; n  = 64 SAI) had an AC during the study: 6.53 (PAI) and 3.17 (SAI) ACs/100 patient-years. Of patients who experienced an AC, 16% (PAI) and 9.4% (SAI) experienced ≥ 1 AC/year. The incidence of adverse events, infectious intercurrent illnesses and infectious serious adverse events were higher in patients with ACs than without ACs. No differences were observed in BMI, HbA 1c, blood pressure and frequencies of diabetes mellitus or hypertension between subgroups (PAI and SAI, with and without ACs). At baseline, PAI patients with AC had higher serum potassium (4.3 ± 0.5 vs 4.2 ± 0.4 mmol/L; P = 0.03) and lower sodium (138.5 ± 3.4 vs 139.7 ± 2.9 mmol/L; P = 0.004) than patients without AC. At last observation, SAI patients with AC had higher hydrocortisone doses than patients without AC (11.9 ± 5.1 vs 10.1 ± 2.9 mg/m 2; P < 0.001).

          Conclusions

          These results demonstrate that concomitant diseases and cardiovascular risk factors do not feature in the risk profile of AC; however, patients with AC had a higher incidence of infectious events.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study.

          Adrenal crisis (AC) is a life-threatening complication of adrenal insufficiency (AI), which according to retrospective data represents a significant clinical complication. Here we aimed to prospectively assess incidence of AC and mortality associated with AC in patients with chronic AI.
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies.

            Adrenal crisis (AC) is a life-threatening complication of adrenal insufficiency (AI). Here, we evaluated frequency, causes and risk factors of AC in patients with chronic AI. In a cross-sectional study, 883 patients with AI were contacted by mail. Five-hundred and twenty-six patients agreed to participate and received a disease-specific questionnaire. Four-hundred and forty-four datasets were available for analysis (primary AI (PAI), n=254; secondary AI (SAI), n=190). Forty-two percent (PAI 47% and SAI 35%) reported at least one crisis. Three hundred and eighty-four AC in 6092 patient years were documented (frequency of 6.3 crises/100 patient years). Precipitating causes were mainly gastrointestinal infection and fever (45%) but also other stressful events (e.g. major pain, surgery, psychic distress, heat and pregnancy). Sudden onset of apparently unexplained AC was also reported (PAI 6.6% and SAI 12.7%). Patients with PAI reported more frequent emergency glucocorticoid administration (42.5 vs 28.4%, P=0.003). Crisis incidence was not influenced by educational status, body mass index, glucocorticoid dose, DHEA treatment, age at diagnosis, hypogonadism, hypothyroidism or GH deficiency. In PAI, patients with concomitant non-endocrine disease were at higher risk of crisis (odds ratio (OR)=2.02, 95% confidence interval (CI) 1.05-3.89, P=0.036). In SAI, female sex (OR=2.18, 95% CI 1.06-4.5, P=0.035) and diabetes insipidus (OR=2.71, 95% CI 1.22-5.99, P=0.014) were associated with higher crisis incidence. AC occurs in a substantial proportion of patients with chronic AI, mainly triggered by infectious disease. Only a limited number of risk factors suitable for targeting prevention of AC were identified. These findings indicate the need for new concepts of crisis prevention in patients with AI.
              • Record: found
              • Abstract: found
              • Article: not found

              Mortality in patients with pituitary disease.

              Pituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing's disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particularly cerebrovascular). Although standardized mortality ratios in pituitary disease are falling due to improved treatment, mortality for many conditions are still elevated above that of the general population, and therefore further measures are needed. Craniopharyngioma patients have a particularly increased risk of mortality as a result of the tumor itself and treatment to control tumor growth; this is a key area for future research in order to optimize the outcome for these patients.

                Author and article information

                Journal
                Eur J Endocrinol
                Eur J Endocrinol
                EJE
                European Journal of Endocrinology
                Bioscientifica Ltd (Bristol )
                0804-4643
                1479-683X
                25 March 2021
                01 June 2021
                : 184
                : 6
                : 761-771
                Affiliations
                [1 ]Endocrinology in Charlottenburg , Berlin, Germany
                [2 ]Department of Endocrinology , Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, UK
                [3 ]Shire Human Genetic Therapies , a member of the Takeda Group of Companies, Cambridge, Massachusetts, USA
                [4 ]Shire International GmbH , a member of the Takeda Group of Companies, Zug, Switzerland
                [5 ]Baxalta Innovations GmbH , a member of the Takeda Group of Companies, Vienna, Austria
                [6 ]Department of Experimental Medicine , Sapienza University of Rome, Rome, Italy
                [7 ]Departments of Endocrinology in Linköping , and Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
                Author notes
                Correspondence should be addressed to M Quinkler Email marcusquinkler@ 123456t-online.de
                Author information
                http://orcid.org/0000-0003-4028-1671
                http://orcid.org/0000-0001-8732-7361
                Article
                EJE-20-1324
                10.1530/EJE-20-1324
                8111327
                33769953
                a60716e5-bf84-436d-8b37-b4020ef850a9
                © 2021 The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 14 November 2020
                : 25 March 2021
                Categories
                Clinical Study

                Endocrinology & Diabetes
                Endocrinology & Diabetes

                Comments

                Comment on this article

                Related Documents Log